Skip to content

Jiannao tongluo granules for convalescent cerebral infarction: a randomized controlled, double-blind trial

Jiannao tongluo granules for convalescent cerebral infarction: a randomized controlled, double-blind trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100048405
Enrollment
Unknown
Registered
2021-07-06
Start date
2021-07-05
Completion date
Unknown
Last updated
2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral Infarction

Interventions

Sponsors

Xinhua Hospital Affiliated to Hubei University of Traditional Chinese Medicine/Hubei Provincial Hospital of Integrated Chinese and Western Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of ''cerebral infarction'' and be confirmed by head CT or MRI examination; 2. Meet the standard of traditional Chinese medicine for stroke - wind-phlegm stasis syndrome; 3. In the recovery period (the course of the disease is 2 weeks to 6 months) 4. Aged 40 to 75 years; 5. For the first time, the vital signs are stable, the consciousness is clear, and the patient can cooperate with the examination and treatment; 6. Voluntarily participate in this study and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with severe cardiovascular and cerebrovascular, liver, kidney, malignant tumors, blood system diseases, and mental diseases; 2. Severe disturbance of consciousness, dementia or certain diseases that affect the evaluation of curative effect, such as aphasia, audio-visual impairment; 3. Transient organic psychosis and other psychotic disorders (such as depression, schizophrenia), or other mental disorders that meet the DSM-IV-R criteria; 4. Patients with other diseases that affect the function of limb movement, and those with limb movement dysfunction caused by claudication, osteoarthritis, rheumatoid arthritis, gouty arthritis, etc., which may affect the nerve or functional examination before treatment; 5. Those who are allergic to the components of the test drug, or have a history of alcohol or drug abuse; 6. Patients who are pregnant or breastfeeding, or who plan to become pregnant within the past 6 months, or who cannot use effective contraceptive measures (sterilization, long-term use of contraceptives/dose, condoms, or partner removal of the vas deferens, etc.); 7. Those who are participating in other clinical trials or have participated in other drug clinical trials within 3 months; 8. Patients who are judged by the investigator to be unsuitable to participate in this trial.

Design outcomes

Primary

MeasureTime frame
National Institute of Health Stroke Scale Score;

Secondary

MeasureTime frame
Fugl-Meyer Assessment Scale Score;TCM Symptom Score;Montreal Cognitive Assessment (MoCA) Score;Modified Rankin Scale Grading;Modified Barthel Index, MBI;

Countries

China

Contacts

Public ContactXia Wen'guang

Xinhua Hospital Affiliated to Hubei University of Traditional Chinese Medicine/Hubei Provincial Hospital of Integrated Chinese and Western Medicine

docxwg@163.com+86 13377897278

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026